$35.31
▼ $-0.12
(-0.34%)
Vol 344K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.8B
ROE
-8.9%
Margin
-2.0%
D/E
516.58
Beta
0.07
52W
$21–$51
Wall Street Consensus
14 analysts · Apr 20265
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
92.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 25.0%
Next Report
May 06, 2026
EPS Estimate: $-0.41
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.41 | — | — |
| Dec 2025 | $0.38 | $0.17 | $-0.21 |
| Sep 2025 | $0.27 | $0.22 | $-0.05 |
| Jun 2025 | $0.01 | $0.13 | +$0.12 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $66.8M | $47.8M | $63.7M | $71.6M | $89.1M |
| Net Income | — | $6.8M | -$17.8M | $5.0M | $1.0M | $6.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -17.5% | -17.5% | -17.5% | -17.5% | -9.0% | -8.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 7.8% | -4.5% | -4.5% | -4.5% | -2.0% | -2.0% |
| Gross Margin | 74.5% | 74.6% | 74.6% | 74.6% | 74.6% | 74.6% |
| D/E Ratio | 447.30 | 447.30 | 447.30 | 447.30 | 516.58 | 516.58 |
| Current Ratio | 0.62 | 0.62 | 0.62 | 0.62 | 2.72 | 2.72 |
Key Ratios
ROA (TTM)
-1.4%
P/S (TTM)
7.26
P/B
17.2
EPS (TTM)
$-0.15
CF/Share
$-0.15
Rev Growth 3Y
+40.2%
52W High
$51.30
52W Low
$20.85
$20.85
52-Week Range
$51.30
Financial Health
Free Cash Flow
$8.0M
Net Debt
$179.0M
Cash
$72.9M
Total Debt
$252.0M
As of Dec 31, 2025
How does HROW compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
HROW valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
7.3
▲
47%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
17.2
▲
709%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
HROW profitability vs Pharmaceuticals peers
ROE
-8.9%
▲
84%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
-2.0%
▲
96%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
74.6%
▲
9%
above
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-1.4%
▲
96%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
HROW financial health vs Pharmaceuticals peers
D/E ratio
516.6
▲
33444%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
2.7
▼
19%
below
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
0.1
▼
92%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
HROW fundamentals radar
HROW
Peer median
Industry
HROW profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio